Related Experiment Videos

Can prognostic factors be applied in treatment selection for aggressive lymphoma patients?

¹Department of Haematology, Centre Hospitalier Lyon-SUD, Hospices Civils de Lyon, France.

Cancer Treatment and Research

|January 1, 1996

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Involvement of the BCL2 Gene in 131 Cases of Non-Hodgkin's B Lymphomas: Analysis of Correlations with Immunological Findings and Cell Cycle.

Leukemia & lymphoma·2016

Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2015

Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2015

See all related articles